Jacobs Levy Equity Management, Inc Arcutis Biotherapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 100,172 shares of ARQT stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,172
Previous 175,909
43.05%
Holding current value
$1.33 Million
Previous $1.64 Million
43.06%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
196Shares Held
130MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC12.3MShares$163 Million0.11% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$145 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$142 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$116 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$114 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $797M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...